Mobile

XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer

Mise à jour : Il y a 5 ans
Référence : NCT00386685

Femme Homme

Extrait

The primary objective of the study is to assess the activity of XRP9881 in combination with trastuzumab. The secondary objectives are safety and pharmacokinetic interaction

Critère d'inclusion

  • Breast Neoplasms

Liens